Evidence map›Paper›PMID 41685351›Full record

ArticleNAR genomics and bioinformatics2026

Nils Eickhoff, Liesbeth Hoekman, Onno Bleijerveld, Andries M Bergman, Wilbert Zwart, Sebastian Gregoricchio

Abstract read
In one paragraph

Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. NAR genomics and bioinformatics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nils EickhoffDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.
Liesbeth HoekmanMass Spectrometry/Proteomics Facility, Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.ORCID https://orcid.org/0000-0002-3552-6390
Onno BleijerveldMass Spectrometry/Proteomics Facility, Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
Andries M BergmanDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.
Wilbert ZwartDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.ORCID https://orcid.org/0000-0002-9823-7289
Sebastian GregoricchioDivision of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.ORCID https://orcid.org/0000-0001-9209-5403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, studies investigating protein-protein interactions on a proteome-wide scale have increased exponentially. These developments were achieved through implementation of new techniques, as well as improvements in mass spectrometry hardware. However, issues specific to this type of technique, such as distinct imputation of random and not-at-random missing proteins, have not been completely addressed. Here, we present

Indexed as

Mass SpectrometryProteomicsSoftwareHumansProteomeProteome

Identifiers

PMID41685351
PMCPMC12891908

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.